Eintrag weiter verarbeiten
Modernized Classification of Cardiac Antiarrhythmic Drugs
Gespeichert in:
| Zeitschriftentitel: | Circulation |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Circulation, 138, 2018, 17, S. 1879-1896 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. |
|---|---|
| author |
Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. |
| spellingShingle |
Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. Circulation Modernized Classification of Cardiac Antiarrhythmic Drugs Physiology (medical) Cardiology and Cardiovascular Medicine |
| author_sort |
lei, ming |
| spelling |
Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/circulationaha.118.035455 <jats:sec> <jats:title>Background:</jats:title> <jats:p>Among his major cardiac electrophysiological contributions, Miles Vaughan Williams (1918–2016) provided a classification of antiarrhythmic drugs that remains central to their clinical use.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We survey implications of subsequent discoveries concerning sarcolemmal, sarcoplasmic reticular, and cytosolic biomolecules, developing an expanded but pragmatic classification that encompasses approved and potential antiarrhythmic drugs on this centenary of his birth.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects. We retain the original Vaughan Williams Classes I through IV but subcategorize these divisions in light of more recent developments, including the existence of Na <jats:sup>+</jats:sup> current components (for Class I), advances in autonomic (often G protein–mediated) signaling (for Class II), K <jats:sup>+</jats:sup> channel subspecies (for Class III), and novel molecular targets related to Ca <jats:sup>2+</jats:sup> homeostasis (for Class IV). We introduce new classes based on additional targets, including channels involved in automaticity, mechanically sensitive ion channels, connexins controlling electrotonic cell coupling, and molecules underlying longer-term signaling processes affecting structural remodeling. Inclusion of this widened range of targets and their physiological sequelae provides a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>We emerge with a modernized classification preserving the simplicity of the original Vaughan Williams framework while aiding our understanding and clinical management of cardiac arrhythmic events and facilitating future developments in this area.</jats:p> </jats:sec> Modernized Classification of Cardiac Antiarrhythmic Drugs Circulation |
| doi_str_mv |
10.1161/circulationaha.118.035455 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM1NDU1 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM1NDU1 |
| institution |
DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| issn |
0009-7322 1524-4539 |
| issn_str_mv |
0009-7322 1524-4539 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
lei2018modernizedclassificationofcardiacantiarrhythmicdrugs |
| publishDateSort |
2018 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Circulation |
| source_id |
49 |
| title |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_unstemmed |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_full |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_fullStr |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_full_unstemmed |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_short |
Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_sort |
modernized classification of cardiac antiarrhythmic drugs |
| topic |
Physiology (medical) Cardiology and Cardiovascular Medicine |
| url |
http://dx.doi.org/10.1161/circulationaha.118.035455 |
| publishDate |
2018 |
| physical |
1879-1896 |
| description |
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Among his major cardiac electrophysiological contributions, Miles Vaughan Williams (1918–2016) provided a classification of antiarrhythmic drugs that remains central to their clinical use.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>We survey implications of subsequent discoveries concerning sarcolemmal, sarcoplasmic reticular, and cytosolic biomolecules, developing an expanded but pragmatic classification that encompasses approved and potential antiarrhythmic drugs on this centenary of his birth.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>
We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects. We retain the original Vaughan Williams Classes I through IV but subcategorize these divisions in light of more recent developments, including the existence of Na
<jats:sup>+</jats:sup>
current components (for Class I), advances in autonomic (often G protein–mediated) signaling (for Class II), K
<jats:sup>+</jats:sup>
channel subspecies (for Class III), and novel molecular targets related to Ca
<jats:sup>2+</jats:sup>
homeostasis (for Class IV). We introduce new classes based on additional targets, including channels involved in automaticity, mechanically sensitive ion channels, connexins controlling electrotonic cell coupling, and molecules underlying longer-term signaling processes affecting structural remodeling. Inclusion of this widened range of targets and their physiological sequelae provides a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>We emerge with a modernized classification preserving the simplicity of the original Vaughan Williams framework while aiding our understanding and clinical management of cardiac arrhythmic events and facilitating future developments in this area.</jats:p>
</jats:sec> |
| container_issue |
17 |
| container_start_page |
1879 |
| container_title |
Circulation |
| container_volume |
138 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346921880256523 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:46:19.459Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Modernized+Classification+of+Cardiac+Antiarrhythmic+Drugs&rft.date=2018-10-23&genre=article&issn=1524-4539&volume=138&issue=17&spage=1879&epage=1896&pages=1879-1896&jtitle=Circulation&atitle=Modernized+Classification+of+Cardiac+Antiarrhythmic+Drugs&aulast=Huang&aufirst=Christopher+L.-H.&rft_id=info%3Adoi%2F10.1161%2Fcirculationaha.118.035455&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346921880256523 |
| author | Lei, Ming, Wu, Lin, Terrar, Derek A., Huang, Christopher L.-H. |
| author_facet | Lei, Ming, Wu, Lin, Terrar, Derek A., Huang, Christopher L.-H., Lei, Ming, Wu, Lin, Terrar, Derek A., Huang, Christopher L.-H. |
| author_sort | lei, ming |
| container_issue | 17 |
| container_start_page | 1879 |
| container_title | Circulation |
| container_volume | 138 |
| description | <jats:sec> <jats:title>Background:</jats:title> <jats:p>Among his major cardiac electrophysiological contributions, Miles Vaughan Williams (1918–2016) provided a classification of antiarrhythmic drugs that remains central to their clinical use.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We survey implications of subsequent discoveries concerning sarcolemmal, sarcoplasmic reticular, and cytosolic biomolecules, developing an expanded but pragmatic classification that encompasses approved and potential antiarrhythmic drugs on this centenary of his birth.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects. We retain the original Vaughan Williams Classes I through IV but subcategorize these divisions in light of more recent developments, including the existence of Na <jats:sup>+</jats:sup> current components (for Class I), advances in autonomic (often G protein–mediated) signaling (for Class II), K <jats:sup>+</jats:sup> channel subspecies (for Class III), and novel molecular targets related to Ca <jats:sup>2+</jats:sup> homeostasis (for Class IV). We introduce new classes based on additional targets, including channels involved in automaticity, mechanically sensitive ion channels, connexins controlling electrotonic cell coupling, and molecules underlying longer-term signaling processes affecting structural remodeling. Inclusion of this widened range of targets and their physiological sequelae provides a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>We emerge with a modernized classification preserving the simplicity of the original Vaughan Williams framework while aiding our understanding and clinical management of cardiac arrhythmic events and facilitating future developments in this area.</jats:p> </jats:sec> |
| doi_str_mv | 10.1161/circulationaha.118.035455 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM1NDU1 |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2018 |
| institution | DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 0009-7322, 1524-4539 |
| issn_str_mv | 0009-7322, 1524-4539 |
| language | English |
| last_indexed | 2024-03-01T17:46:19.459Z |
| match_str | lei2018modernizedclassificationofcardiacantiarrhythmicdrugs |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 1879-1896 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Circulation |
| source_id | 49 |
| spelling | Lei, Ming Wu, Lin Terrar, Derek A. Huang, Christopher L.-H. 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/circulationaha.118.035455 <jats:sec> <jats:title>Background:</jats:title> <jats:p>Among his major cardiac electrophysiological contributions, Miles Vaughan Williams (1918–2016) provided a classification of antiarrhythmic drugs that remains central to their clinical use.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We survey implications of subsequent discoveries concerning sarcolemmal, sarcoplasmic reticular, and cytosolic biomolecules, developing an expanded but pragmatic classification that encompasses approved and potential antiarrhythmic drugs on this centenary of his birth.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects. We retain the original Vaughan Williams Classes I through IV but subcategorize these divisions in light of more recent developments, including the existence of Na <jats:sup>+</jats:sup> current components (for Class I), advances in autonomic (often G protein–mediated) signaling (for Class II), K <jats:sup>+</jats:sup> channel subspecies (for Class III), and novel molecular targets related to Ca <jats:sup>2+</jats:sup> homeostasis (for Class IV). We introduce new classes based on additional targets, including channels involved in automaticity, mechanically sensitive ion channels, connexins controlling electrotonic cell coupling, and molecules underlying longer-term signaling processes affecting structural remodeling. Inclusion of this widened range of targets and their physiological sequelae provides a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>We emerge with a modernized classification preserving the simplicity of the original Vaughan Williams framework while aiding our understanding and clinical management of cardiac arrhythmic events and facilitating future developments in this area.</jats:p> </jats:sec> Modernized Classification of Cardiac Antiarrhythmic Drugs Circulation |
| spellingShingle | Lei, Ming, Wu, Lin, Terrar, Derek A., Huang, Christopher L.-H., Circulation, Modernized Classification of Cardiac Antiarrhythmic Drugs, Physiology (medical), Cardiology and Cardiovascular Medicine |
| title | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_full | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_fullStr | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_full_unstemmed | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_short | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| title_sort | modernized classification of cardiac antiarrhythmic drugs |
| title_unstemmed | Modernized Classification of Cardiac Antiarrhythmic Drugs |
| topic | Physiology (medical), Cardiology and Cardiovascular Medicine |
| url | http://dx.doi.org/10.1161/circulationaha.118.035455 |